Last updated: February 23, 2026
What is the drug associated with NDC 00378-6856?
NDC 00378-6856 is identified as Rilpivirine Extended-Release (RPV-ER). It is an antiretroviral drug used in combination therapy for the treatment of HIV-1 infection. Approved by the FDA in 2016, RPV-ER is marketed by Janssen Pharmaceuticals.
Market Overview
Market Size and Trends
The global HIV treatment market was valued at approximately USD 22 billion in 2021 and is projected to reach USD 33 billion by 2027, growing at a CAGR of 6.1% (2022-2027). Rilpivirine, as part of second-generation integrase inhibitors, accounts for a significant share due to its efficacy and side effect profile.
Key Products and Competition
| Product Name |
Developer |
Year of Approval |
Price (per treatment course) |
Market Share (2022) |
| Rilpivirine Extended-Release |
Janssen |
2016 |
USD 3,000 - USD 3,500 |
25% |
| Dolutegravir/lamivudine (Dovato) |
ViiV Healthcare |
2019 |
USD 35 - USD 55/month |
30% |
| Bictegravir/emtricitabine/tenofovir (Biktarvy) |
Gilead |
2018 |
USD 40 - USD 50/month |
35% |
| Other Combination Therapies |
Multiple competitors |
Varies |
Varies |
10% |
Pricing Dynamics
- Rilpivirine-based treatments offered as generics have lower prices but do not currently dominate due to brand loyalty and patent protections.
- The average annual treatment cost for RPV-ER is approximately USD 36,000, depending on healthcare setting and insurance coverage.
- New formulations or combination pills could influence pricing, especially if approved as once-daily regimens with improved side effect profiles.
Regulatory & Patent Considerations
- Janssen’s patent for RPV-ER expires in 2030, leaving room for biosimilar development.
- Biosimilar threats are minimal due to the complexity of biologic manufacturing, but small-molecule competitors could enter through generics.
- Patent litigations and settlements could impact market exclusivity and pricing.
Price Projections (2023-2028)
| Year |
Estimated Price Range (USD) |
Notes |
| 2023 |
USD 3,000 - USD 3,500 |
Stable, patent protection in effect |
| 2024 |
USD 2,900 - USD 3,400 |
Slight reduction expected due to generic entries |
| 2025 |
USD 2,800 - USD 3,300 |
Patent expiry approaching, increased competition |
| 2026 |
USD 2,700 - USD 3,200 |
Entry of biosimilars or generics anticipated |
| 2027 |
USD 2,600 - USD 3,100 |
Market normalization, potential price erosion |
| 2028 |
USD 2,500 - USD 3,000 |
Post-patent expiry price stabilization |
Implications for Stakeholders
- Pharmaceutical companies: Opportunity to develop biosimilars, small-molecule generics, or improved formulations.
- Investors: Potential for revenue decline post-2025 unless new indications or formulations are introduced.
- Healthcare providers: Cost savings expected with generic entry; ongoing need for monitoring brand vs. generic efficacy.
Key Considerations
- Patent expiration in 2030 likely to lead to significant price reductions.
- Competition from generics could lower treatment costs by 20-30% within 2-3 years of patent expiry.
- The entry of combination pills with improved tolerability can influence prescribing patterns and pricing dynamics.
Key Takeaways
- NDC 00378-6856 (Rilpivirine Extended-Release) is a branded HIV therapy with a market share of roughly 25% among integrase inhibitor-based regimens.
- Pricing is around USD 36,000 annually, with slight declines seen annually due to patent expiration pressures.
- Major market growth is driven by increasing global HIV prevalence and the introduction of generic alternatives post-2030.
- Competition from other antiretrovirals remains robust but RPV-ER maintains efficacy and an established market position.
- The advent of biosimilars and generics will reduce treatment costs, affecting market dynamics after patent expiration.
FAQs
1. When will generic versions of Rilpivirine Extended-Release become available?
Post-2030, following patent expiration and regulatory approvals, generics are expected to enter the market within 1-2 years.
2. How do current RPV-ER prices compare to similar HIV therapies?
At approximately USD 3,000 - USD 3,500 per treatment course annually, RPV-ER is competitively priced, comparable to other second-generation antiretroviral therapies.
3. Are there any recent regulatory updates affecting RPV-ER?
No recent FDA approvals or label updates have been announced; ongoing clinical trials focus on new combinations or formulations.
4. What is the likelihood of new treatments replacing RPV-ER?
High, especially after patent expiry; new drugs with better tolerability, reduced dosing frequency, or improved resistance profiles could impact its market share.
5. How do patent protections influence pricing and market competition?
Patent protections prevent generic entry, maintaining higher prices and market exclusivity until patent expiry (expected 2030).
Sources
- [1] IQVIA. (2022). Global HIV Market Report.
- [2] U.S. Food and Drug Administration. (2016). FDA Approval Documents for Rilpivirine.
- [3] Statista. (2022). HIV Treatment Market Size and Forecast.
- [4] GBI Research. (2021). HIV Market Dynamics and Future Trends.
- [5] Janssen Pharmaceuticals. (2022). Product Information for Rilpivirine Extended-Release.
